Cellectis to Report Third Quarter Financial Results on November 7, 2025
Published on October 31, 2025
New York, NY - October 31, 2025 - Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the third quarter 2025 ending September 30, 2025 on Friday, November 7, 2025 after the close of the US market.
The press release will be available in the Investors section of Cellectis’ website: https://www.cellectis.com/en/investors/press-releases/
Cellectis will not host a conference call to discuss these results. Our investors relations team remains available for questions at investors@cellectis.com